{"createdAt":"8/2/2020, 2:33:41 PM","timestamp":1596393221478,"Company ID number":"611","DMX_ISSUER_NAME":"Chengdu Kanghong Pharmaceutical Group Co Ltd","DMX_ISSUER_ID":"IID000000002735218","Country of Classification":"CHINA","name":"Chengdu Kanghong Pharmaceutical Group Co Ltd ","code":"002773","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"成都康弘药业集团股份有限公司_柯尊洪","group":"board","name":"柯尊洪","title":"董事长,董事","isMale":true,"age":"66","degree":"本科","salary":"132.0万","stockAmount":"2.253亿","description":"柯尊洪先生,1954年7月出生,中国国籍,拥有新加坡居留权,本科学历,高级工程师,执业药师,系第十二届全国人大代表,中国化学制药工业协会副会长,世界中医药学会联合会-心血管病专业委员会第三届理事会副会长,四川省委省政府决策咨询委员会委员,四川省商会副会长,曾任第十一届全国人大代表,中国科学技术协会第八届全国委员会委员,第十届四川省人大常委会委员,第八届四川省政协委员。曾荣获全国首届优秀中国特设社会主义事业建设者、四川省优秀民营企业家、四川省优秀共产党员、成都市优秀共产党员、成都市劳动模范、2006年度唯一的成都市科技杰出贡献奖。从事医药行业工作30余年,曾任华西医科大学附属第一医院药剂科副主任,海南曼克星制药厂总经理,康弘制药总经理、董事,成都康弘药业集团股份有限公司总裁。自1998年至今担任成都康弘药业集团股份有限公司董事长。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_柯潇","group":"board","name":"柯潇","title":"董事","isMale":true,"age":"37","degree":"本科","salary":"127.6万","stockAmount":"7176万","description":"柯潇先生,1983年11月出生,中国国籍,无境外居留权,美国旧金山大学理学学士,曾任成都康弘药业集团股份有限公司总裁助理兼市场部副总监。现任成都康弘药业集团股份有限公司董事、副总裁。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_钟建荣","group":"board","name":"钟建荣","title":"董事","isMale":false,"age":"63","degree":"大专","salary":"119.5万","stockAmount":"1058万","description":"钟建荣女士,1957年1月出生,中国国籍,拥有新加坡居留权,雅安财贸学校会统专业毕业。从事组织人事工作10年,医药行业工作20余年,先后在芦山县委组织部、成都蜀锦厂组织科、成都市医药公司及成都康弘药业集团股份有限公司工作。现任成都康弘药业集团股份有限公司董事、副总裁。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_殷劲群","group":"board","name":"殷劲群","title":"董事","isMale":true,"age":"48","degree":"硕士","salary":"280.1万","stockAmount":"42.56万","description":"殷劲群先生,1972年11月出生,中国国籍,无境外居留权,北京工商大学生物化学工程系本科毕业,北京大学国际商学院BIMBA。曾在北京第四制药厂、西安杨森制药有限公司、美国雅培制药有限公司、拜耳医药保健有限公司任职。现任成都康弘药业集团股份有限公司副总裁。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_王霖","group":"board","name":"王霖","title":"董事","isMale":true,"age":"52","degree":"博士","salary":"0.00","stockAmount":"-","description":"王霖先生,1968年7月出生,博士研究生学历,中国香港籍。王霖先生1994年8年至2002年8月,历任中国投融资担保有限公司高级经理、中金公司高级经理。王霖先生现任CDHInvestmentsManagement(HongKong)Limited董事总经理、GingkoCompanyLimited董事、GoldenGingkoCompanyLimited董事、北京达康医疗投资有限公司董事、皇明太阳能股份有限公司董事、南京明基医院有限公司董事、苏州明基医院有限公司董事、明基(南京)医院管理咨询有限公司董事、成都康弘药业集团股份有限公司董事、鼎晖股权投资管理(天津)有限公司监事、天津泰鼎投资有限公司监事、深圳市鼎晖创业投资管理有限公司监事。王霖先生2018年7月至今,任成都先导董事职务。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_CHENSU","group":"board","name":"CHENSU","title":"董事","isMale":true,"age":"52","degree":"硕士","salary":"--","stockAmount":"-","description":"CHEN SU,1968年2月出生,美国国籍,美国俄亥俄州托莱多大学化学工程硕士,美国加州大学洛杉矶分校工商管理硕士,美国加州州立大学计算机科学硕士。在美国主导超过10个生物制品的开发和商业生产,获得2006年度美国总统绿色化学挑战奖。为四川省“千人计划”特聘专家,四川省“千人计划”创新团队带头人。现任成都康弘药业集团股份有限公司副总裁。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_张强","group":"board","name":"张强","title":"独立董事","isMale":true,"age":"62","degree":"博士","salary":"0.00","stockAmount":"-","description":"张强,男,汉族,1958年生,博士研究生学历,历任四川抗菌素工业研究所课题负责人和研究室副主任,北京大学副教授、硕士生导师、教授、博士生导师,研究室副主任、主任、药剂学系副主任、主任,北京大学药学院副院长。曾任中国药学会药剂专业委员会主任委员和世界控释协会中国分会首任主席。现任北京大学药学院教授、博士生导师。现任中国药学会常务理事和纳米药物专业委员会副主任,国家药典委员会制剂专业委员会副主任,北京市重点实验室主任,《药学学报》(中、英文版)副主编、《中国药学杂志》(中、英文版)副主编,《JControlledRelease》等多种国际杂志编委等,现任成都康弘药业集团股份有限公司独立董事。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_屈三才","group":"board","name":"屈三才","title":"独立董事","isMale":true,"age":"46","degree":"硕士","salary":"12.00万","stockAmount":"-","description":"屈三才先生,1974年2月出生,中国国籍,无境外居留权,毕业于西南政法大学国际法专业,法学硕士。曾任重庆邮电大学教师、重庆红岩律师事务所副主任。现任上海锦天城(重庆)律师事务所主任暨高级合伙人,重庆市律师协会知识产权业务委员会委员,重庆市仲裁委员会仲裁员,西南大学法律硕士专业硕士研究生兼职指导教师,重庆市渝北区民营企业商事纠纷人民调解委员会兼职调解员,重庆银行业人民调解委员会调解员。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_张宇","group":"board","name":"张宇","title":"独立董事","isMale":true,"age":"42","degree":"硕士","salary":"12.00万","stockAmount":"-","description":"张宇先生,1978年2月出生,中国国籍,无境外居留权,毕业于上海财经大学会计专业,会计学硕士。曾任上海九洲会计师事务所有限公司项目经理。现任立信会计师事务所(特殊普通合伙)权益合伙人,中国证监会宁波证监局企业改制上市专家小组专家,上海立信会计学院兼职副教授、硕士研究生导师,宁波市仲裁委员会仲裁员。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_龚文贤","group":"supervisoryCommittee","name":"龚文贤","title":"监事会主席","isMale":true,"age":"73","degree":"本科","salary":"60.00万","stockAmount":"26.45万","description":"龚文贤先生,1947年1月出生,中国国籍,无境外居留权,本科学历,高级工程师,从事医药行业工作30余年。曾任华西医科大学附属第一医院药剂科副主任,康弘制药副总经理、总经理,成都康弘药业集团股份有限公司副董事长、总经理,成都市第十五届人大代表、双流县第十六届人大代表。现任成都康弘药业集团股份有限公司监事会主席。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_杨建群","group":"supervisoryCommittee","name":"杨建群","title":"监事","isMale":false,"age":"46","degree":"本科","salary":"40.78万","stockAmount":"-","description":"杨建群女士,1974年6月出生,中国国籍,无境外居留权,本科学历。曾任康弘制药市场部主任,成都康弘药业集团股份有限公司总裁办副主任、主任。现任成都康弘药业集团股份有限公司行政部总监。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_杨寅莹","group":"supervisoryCommittee","name":"杨寅莹","title":"职工监事","isMale":false,"age":"34","degree":"本科","salary":"21.09万","stockAmount":"-","description":"杨寅莹女士,1986年5月出生,中国国籍,无境外居留权,本科学历。现就职于康弘药业人力资源部,任康弘药业人力资源部企业文化办主任。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_柯潇","group":"manager","name":"柯潇","title":"总裁","isMale":true,"age":"37","degree":"本科","salary":"127.6万","stockAmount":"7176万","description":"柯潇先生,1983年11月出生,中国国籍,无境外居留权,美国旧金山大学理学学士,曾任成都康弘药业集团股份有限公司总裁助理兼市场部副总监。现任成都康弘药业集团股份有限公司董事、副总裁。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_钟建军","group":"manager","name":"钟建军","title":"董事会秘书,副总裁,财务总监","isMale":true,"age":"53","degree":"硕士","salary":"142.9万","stockAmount":"890万","description":"钟建军先生,1967年3月出生,中国国籍,无境外居留权,硕士研究生学历。曾任康弘制药财务经理、财务总监,成都康弘药业集团股份有限公司董事。现任成都康弘药业集团股份有限公司副总裁、财务总监、董事会秘书。钟建军先生已于2011年取得了深圳证券交易所颁发的《董事会秘书资格证书》,其任职资格符合《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司董事会秘书及证券事务代表资格管理办法》和《公司章程》等有关规定。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_钟建荣","group":"manager","name":"钟建荣","title":"副总裁","isMale":false,"age":"63","degree":"大专","salary":"119.5万","stockAmount":"1058万","description":"钟建荣女士,1957年1月出生,中国国籍,拥有新加坡居留权,雅安财贸学校会统专业毕业。从事组织人事工作10年,医药行业工作20余年,先后在芦山县委组织部、成都蜀锦厂组织科、成都市医药公司及成都康弘药业集团股份有限公司工作。现任成都康弘药业集团股份有限公司董事、副总裁。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_殷劲群","group":"manager","name":"殷劲群","title":"副总裁","isMale":true,"age":"48","degree":"硕士","salary":"280.1万","stockAmount":"42.56万","description":"殷劲群先生,1972年11月出生,中国国籍,无境外居留权,北京工商大学生物化学工程系本科毕业,北京大学国际商学院BIMBA。曾在北京第四制药厂、西安杨森制药有限公司、美国雅培制药有限公司、拜耳医药保健有限公司任职。现任成都康弘药业集团股份有限公司副总裁。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_倪静","group":"manager","name":"倪静","title":"副总裁","isMale":false,"age":"44","degree":"本科","salary":"318.5万","stockAmount":"14.1万","description":"倪静,1976年1月出生,中国国籍,无境外居留权,湖南中医药大学学士学位,担任中医药产教融合促进委员会眼科专业委员会副主任委员,曾在西安杨森制药有限公司,美国雅培制药有限公司,北京诺华制药有限公司任职,现任成都康弘药业集团股份有限公司执行副总裁。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_QUNKEVINFANG","group":"manager","name":"QUNKEVINFANG","title":"副总裁","isMale":true,"age":"57","degree":"博士","salary":"16.67万","stockAmount":"-","description":"QUN KEVIN FANG先生,1963年1月份出生于中国浙江省,美国国籍,美国麻省理工学院哲学博士,中组部国家“千人计划”专家。曾担任美中生物医药协会(CABA)会长及新英格兰美中医药开发协会(SAPA-NE)执行理事。曾在美国麻州Sepracor及Sunovion任职为高级总监。现任成都康弘药业集团股份有限公司新药研究院院长。","lastUpdated":"2019-12-28"},{"id":"成都康弘药业集团股份有限公司_XIAOFENG","group":"manager","name":"XIAOFENG","title":"副总裁","isMale":true,"age":"55","degree":"硕士","salary":"144.7万","stockAmount":"-","description":"XIAO FENG,1965年4月出生,美国国籍,中国居住权,北京大学医学部肿瘤学硕士,在加州大学医学中心进行毕业后研发工作;中国人体修复技术和材料创新联盟专家委员会委员,吉林省生物制药产业技术创新战略联盟专家委员会会员,吉林省高层次创新领军人才,长春新区“长白慧谷”高层次创新人才,成都市“蓉漂计划”创新人才。曾任Duoont-Merck制药公司资深科学家,Amgen(Abgenix)制药公司抗体研发高级经理,Lexicon制药公司生物药研发总监,金斯瑞生产研发副总裁,药明康德生物制药副总裁,金赛药业研究院院长及吉林省抗衰老及心血管疾病生物精准医疗科技创新中心主任。现任成都康弘药业集团股份有限公司生物新药研究院院长。","lastUpdated":"2019-12-28"}],"companyName":"成都康弘药业集团股份有限公司","province":"四川省","englishName":"Chengdu Kanghong Pharma Grp Co Ltd","industry":"医药生物 — 化学制药","website":"www.cnkh.com","mainBusiness":"以技术创新为主线推动研发、生产和销售三大板块，以临床需求为导向，持续专注于医药行业致力于中成药、化学药及生物制品的研发、生产和销售，专业创新、专业服务","productsName":["中成药","化学药","生物制品","医疗器械"],"actualController":"柯潇、柯尊洪、钟建荣","actualControllerSharePercentage":"31.55、26.06、2.88%","registeredCapital":"8.76亿元","employeeAmount":"4201","phone":"86-028-87502055","location":"四川省成都市金牛区蜀西路36号","chineseDescription":"成都康弘药业集团股份有限公司主营业务为药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司目前上市产品主要为：康柏西普眼用注射液、松龄血脉康胶囊、舒肝解郁胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、枸橼酸莫沙必利分散片、右佐匹克隆片等十六个药品和两个医疗器械。","foundedDate":"1996-10-03","goPublicDate":"2015-06-26","companyHistory":"成都康弘药业集团股份有限公司（以下简称本公司或公司），《营业执照》统一社会信用代码号：\n　　91510100633116839D；住所：成都市金牛区蜀西路36号；注册资本：\n　　67,495.406万元；法定代表人：柯尊洪；公司类型：其他股份有限公司（上市）；经营期限：\n　　1996年10月3日至永久。\n　　本公司前身为成都伊尔康制药有限公司，系经成都市经济体制改革委员会以成体改（1998）148号文件批准，于1998年10月8日由全民所有制企业成都济民制药厂改制成立的公司，由成都诺伊科技实业公司[现已更名为成都康弘科技实业（集团）有限公司，以下均简称为康弘科技]和成都伊尔康科技实业有限公司分别以货币资金70万元和30万元出资成立，注册资本和实收资本为100万元。\n　　1998年11月23日，经成都市工商行政管理局核准，本公司名称变更为成都大西南制药有限公司。\n　　1998年12月3日，本公司注册资本和实收资本增加至2,000万元。\n　　2001年2月26日，经四川省人民政府以川府函[2001]25号文批准，本公司由成都大西南制药有限公司变更为成都大西南制药股份有限公司。并经创立大会决议同意增资，将公司截至2000年9月30日的净资产31,123,833.87元按1:1折股为31,123,833股，折余金额0.87元计入资本公积，变更后注册资本和股本为31,123,833.00元。\n　　2007年12月28日，根据2007年第三次临时股东大会会议决议，本公司注册资本和股本增加至63,333,333.00元。新增注册资本32,209,500.00元由新股东成都九州汇源科技有限公司和康弘科技认缴。其中：成都九州汇源科技有限公司认购4,736,905股，每股价格6.77元，共计32,068,850.78元，出资方式为成都九州汇源科技有限公司持有的成都康弘医药贸易有限公司95%的股权，以截至2007年9月30日经审计、评估作价32,068,850.78元；康弘科技认购27,472,595股，每股价格6.77元，共计185,989,468.15元，出资方式为康弘科技持有的成都康弘制药有限公司100%的股权、四川康弘医药贸易有限公司81%的股权、四川济生堂药业有限公司91.25%的股权、康弘赛金（成都）药业有限公司50%的股权和成都康弘生物科技有限公司51%的股权等5项股权，以截至2007年9月30日经审计、评估作价216,815,573.61元，超过认购部分的金额为30,826,105.46元，由本公司向康弘科技现金支付。\n　　2008年3月6日，经成都市工商行政管理局核准，本公司更名为成都康弘药业集团股份有限公司。\n　　2008年9月3日，根据2007年度股东大会决议，本公司以截止2007年12月31日总股本63,333,333股为基数，以资本公积金每10股转增13.68421065股，共转增86,666,667股，转增后本公司注册资本和股本增加至150,000,000.00元。\n　　2011年6月24日，根据本公司召开的2010年度股东大会决议和修改后章程的规定：（1）本公司以资本公积和未分配利润转增股本181,200,000.00元，基准日期为2010年12月31日；（2）北京鼎晖维森创业投资中心（有限合伙）（以下简称“鼎晖维森”）、北京鼎晖维鑫创业投资中心（有限合伙）（以下简称“鼎晖维鑫”）、天津鼎晖股权投资一期基金（有限合伙）（以下简称“天津一期”）和天津鼎晖元博股权投资基金（有限合伙）（以下简称“鼎晖元博”）以共计人民币260,870,400.00元认购本公司新增的每股面值人民币1元的普通股2,880万股，每股价格超过人民币1元的部分计23,207.04万元列为本公司资本公积；（3）康弘科技将其所持有的本公司的股份7,200,000股转让给新股东鼎晖维鑫4,319,895股、上海鼎青投资管理有限公司（以下简称“上海鼎青”）2,880,105股。\n　　2014年1月23日，根据本公司召开的2014年度第一次临时股东大会决议和修改后章程的规定：本公司以2012年12月31日资本公积转增股本，每10股转增1.111111111股，共计转增4,000.00万股。转增后股本变更为4亿股。\n　　根据本公司股东大会决议、公司章程和中国证监会2015年6月9日《中国证券监督管理委员会关于成都康弘药业集团股份有限公司首次公开发行股票的批复》（证监许可[2015]1198号）文核准，公司向社会公开发行人民币普通股4,560万股，每股面值人民币1元。本次股票发行后的注册资本（股本）变更为人民币445,600,000.00元。\n　　2016年1月14日,根据康弘药业2015年第二次临时股东大会通过的《成都康弘药业集团股份有限公司2015年限制性股票激励计划（草案）及其摘要》和第五届董事会第十三次会议通过的《关于向激励对象授予限制性股票的议案》决议：对432名公司员工进行股权激励，授予4,256,040.00股，授予价为43.96元/股，本次新增注册资本（股本）为4,256,040.00元。变更后注册资本（股本）为人民币449,856,040.00元。\n　　2016年6月8日,根据康弘药业2015年股东大会通过的《2015年度利润分配及资本公积转增股本的预案》和修改后章程的规定，康弘药业申请增加注册资本人民币224,928,020.00元，由资本公积转增股本，变更后的注册资本（股本）为人民币674,784,060.00元。\n　　根据康弘药业2015年第二次临时股东大会通过的《成都康弘药业集团股份有限公司2015年限制性股票激励计划（草案）及其摘要》、第五届董事会第十三次会议通过的《关于向激励对象授予限制性股票的议案》决议和第六届董事会第四次会议通过的《关于调整限制性股票激励计划相关事项的议案》决议：对2名公司员工进行股权激励，授予价格28.80元/股。截至2016年12月19日，本次新增注册资本（股本）为170,000.00元，变更后的注册资本（股本）为人民币674,954,060.00元。\n　　截至2016年12月31日，本公司注册及实收资本（股本）为674,954,060.00元。公司于2017年1月在中国证券登记结算有限责任公司深圳分公司办理完成了授予的限制性股票登记手续，并于2017年2月完成了工商变更登记手续。\n　　2019年5月20日，根据康弘药业2018年股东大会通过的《2018年度利润分配及资本公积转增股本的预案》和修改后章程的规定，康弘药业申请增加注册资本人民币202,061,004.00元，由资本公积转增股本，变更后的注册资本（股本）为人民币875,597,684.00元。\n　　根据康弘药业第六届董事会第十次会议和第六届监事会第八次会议审议通过的《关于回购注销部分已授予但尚未解锁的限制性股票的议案》：回购注销233名限售股股东持有的已授权但尚未解锁的限制性股票，减少注册资本（股本）人民币744,033.00元，变更后的注册资本（股本）为人民币674,210,027.00元。\n　　公司注册地、总部地址：成都市金牛区蜀西路36号。\n　　根据康弘药业第六届董事会第十次会议和第六届监事会第八次会议审议通过的《关于回购注销部分已授予但尚未解锁的限制性股票的议案》:回购注销233名限售股股东持有的已授权但尚未解锁的限制性股票，减少注册资本（股本）人民币744,033.00元,并于2018年2月2日完成工商变更手续，变更后的注册资本（股本）为人民币674,210,027.00元。收起▲","shareholders":[{"organizationId":"T000365649","holderName":"成都康弘科技实业(集团)有限公司","totalShare":"2.92亿","sharePercentage":"33.35%"},{"organizationId":"","holderName":"柯尊洪","totalShare":"2.25亿","sharePercentage":"25.73%"},{"organizationId":"","holderName":"柯潇","totalShare":"7176.00万","sharePercentage":"8.20%"},{"organizationId":"","holderName":"龚静","totalShare":"3417.96万","sharePercentage":"3.90%"},{"organizationId":"","holderName":"中国建设银行股份有限公司-兴全社会责任混合型证券投资基金","totalShare":"1462.25万","sharePercentage":"1.67%"},{"organizationId":"","holderName":"赵兴平","totalShare":"1222.03万","sharePercentage":"1.40%"},{"organizationId":"","holderName":"钟建荣","totalShare":"1057.95万","sharePercentage":"1.21%"},{"organizationId":"","holderName":"钟建军","totalShare":"890.00万","sharePercentage":"1.02%"},{"organizationId":"","holderName":"招商银行股份有限公司-兴全轻资产投资混合型证券投资基金(LOF)","totalShare":"739.66万","sharePercentage":"0.84%"},{"organizationId":"","holderName":"兴业全球基金-兴业银行-兴全-股票红利特定多客户资产管理计划","totalShare":"722.03万","sharePercentage":"0.82%"}],"englishDescription":"Chengdu Kanghong Pharmaceutical Group Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines, chemical drugs and biological products. The Company鈥檚 main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, Keluoxin capsules, venlafaxine hydrochloride capsules and sustained release tablets, aripiprazole tablets and orally disintegrating tablets, mosapride citrate tablets and dispersible tablets, dexzopiclone tablets, Shuganjieyu capsules, Danshu capsules and Yiqing capsules, among others. The Company distributes its products in domestic market.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"61.17","Price to sales (ttm)":"13.18","Price to book (mrq)":"8.38","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"28.74","Lt debt to equity (mrq)":"28.74","Return on investment (ttm)":"11.76","Return on equity (ttm)":"10.70","Income statement":{"Revenue":"3,257.43","Total revenue":"3,257.43","Cost of revenue, total":"264.78","Gross profit":"2,992.65","Selling/general/admin. expenses, total":"1,989.37","Research & development":"276.19","Depreciation/amortization":"34.85","Interest exp.(inc.),net-operating, total":"(54.58)","Unusual expense (income)":"2.79","Other operating expenses, total":"(73.93)","Total operating expense":"2,439.47","Operating income":"817.96","Other, net":"17.22","Net income before taxes":"835.18","Provision for income taxes":"116.99","Net income after taxes":"718.19","Net income before extra. items":"718.19","Net income":"718.19","Income available to com excl extraord":"718.19","Income available to com incl extraord":"718.19","Diluted net income":"718.19","Diluted weighted average shares":"873.56","Diluted eps excluding extraord items":"0.82","Dps - common stock primary issue":"0.28","Diluted normalized eps":"0.82","Gain (loss) on sale of assets":"(0.50)","Minority interest":"(3.37)"},"Balance sheet":{"Cash":"0.06","Cash & equivalents":"2,283.69","Cash and short term investments":"2,283.75","Accounts receivable - trade, net":"393.04","Total receivables, net":"448.46","Total inventory":"263.14","Prepaid expenses":"29.90","Other current assets, total":"0.18","Total current assets":"3,025.43","Property/plant/equipment, total - gross":"1,902.08","Accumulated depreciation, total":"(489.76)","Property/plant/equipment, total - net":"1,412.32","Goodwill, net":"214.84","Intangibles, net":"1,093.17","Long term investments":"8.81","Other long term assets, total":"72.44","Total assets":"5,827.02","Accounts payable":"240.27","Accrued expenses":"279.87","Notes payable/short term debt":"0.00","Other current liabilities, total":"227.04","Total current liabilities":"747.17","Long term debt":"0.00","Total long term debt":"0.00","Total debt":"0.00","Deferred income tax":"2.68","Other liabilities, total":"456.62","Total liabilities":"1,206.47","Common stock, total":"873.56","Additional paid-in capital":"377.02","Retained earnings (accumulated deficit)":"3,370.04","Treasury stock - common":"(1.12)","Other equity, total":"1.06","Total equity":"4,620.55","Total liabilities & shareholders' equity":"5,827.02","Total common shares outstanding":"873.56","Tangible book value per share, common eq":"3.79","Minority interest":"23.23","Note receivable - long term":"52.19","Current port. of  lt debt/capital leases":"0.00"},"Cash flow":{"Cash receipts":"3,619.44","Cash payments":"(202.85)","Cash taxes paid":"(439.67)","Changes in working capital":"(2,164.77)","Cash from operating activities":"812.15","Capital expenditures":"(962.88)","Other investing cash flow items, total":"168.92","Cash from investing activities":"(793.95)","Financing cash flow items":"(42.35)","Total cash dividends paid":"(187.90)","Cash from financing activities":"(230.25)","Foreign exchange effects":"2.67","Net change in cash":"(209.38)","Issuance (retirement) of debt, net":"(5.00)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"47.77","52 Week High":"51.72","52 Week Low":"29.82","Pricing date":"","10 Day Average Trading Volume":"6.70","Market Capitalization":"41,827.30","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"129.72","Beta":"0.83","1 Day Price Change":"-1.87","13 Week Price Return (Daily)":"24.47","26 Week Price Return (Daily)":"24.89","5 Day Price Return (Daily)":"5.08","52 Week Price Return (Daily)":"41.67","Year To Date Price Return (Daily)":"29.21","Month to Date Price Return (Daily)":"-3.69","Price Relative to S&P500 (4 Week)":"-6.44","Price Relative to S&P500 (13 Week)":"-2.15","Price Relative to S&P500 (26 Week)":"-2.18","Price Relative to S&P500 (52 Week)":"-3.73","Price Relative to S&P500 (YTD)":"-1.17"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.82","EPS excl. Extra Items (TTM)":"0.78","EPS Normalized (Annual)":"0.82","Revenue per Share (Annual)":"3.73","Revenue per Share (TTM)":"3.62","Book Value (Per Share Annual)":"5.29","Book Value (Per Share Quarterly)":"5.70","Tangible Book Value (Per Share Annual)":"3.79","Tangible Book Value (Per Share Quarterly)":"4.06","Cash Per Share (Per Share Annual)":"2.61","Cash Per Share (Per Share Quarterly)":"4.24","Cash Flow (Per Share Annual)":"0.93","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.28","Dividends (Per Share TTM)":"0.28","EBITD (Per Share TTM)":"0.82","EPS Basic excl. Extra Items (Annual)":"0.82","EPS Basic excl. Extra Items (TTM)":"0.78","EPS incl. Extra Items (Annual)":"0.82","EPS incl. Extra Items (TTM)":"0.78","Free Cash Flow (Per Share TTM)":"-0.31","Dividend (Per Share 5Y)":"0.19"},"Valuation":{"P/E excl. Extra Items (Annual)":"58.10","P/E excl. Extra Items (TTM)":"61.17","P/E Normalized (Annual)":"57.91","Price to sales (Annual)":"12.84","Price to sales (TTM)":"13.18","Price to Tangible Book (Annual)":"12.63","Price to Tangible Book (Quarterly)":"11.80","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"9.03","Price to Book (Quarterly)":"8.38","P/E Basic excl. Extra Items (TTM)":"50.43","P/E excl. Extra Items High (TTM)":"91.21","P/E excl. Extra Items Low (TTM)":"30.71","P/E incl. Extra Items (TTM)":"61.17","Net Debt (Interim)":"-2,272.01","Net Debt (Annual)":"-2,283.75","Dividend Yield (5Y)":"0.47","Dividend Yield":"0.59","Current Dividend Yield (TTM)":"0.59"},"Financial Strength":{"Free Cash Flow (Annual)":"-338.63","Current Ratio (Annual)":"4.05","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"34.14","Quick Ratio (Annual)":"3.70","Total Debt/Total Equity (Annual)":"0.00","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"7.59","Long Term Debt/Equity (Quarterly)":"28.74","Quick Ratio (Quarterly)":"7.13","Total Debt/Total Equity (Quarterly)":"28.74","Free Cash Flow (TTM)":"-269.47","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"35.85"},"Margins":{"Gross Margin (Annual)":"91.87","Gross Margin (TTM)":"90.25","Net Profit Margin % (Annual)":"22.05","Net Profit Margin (TTM)":"21.55","Operating Margin (Annual)":"25.11","Operating Margin (TTM)":"24.24","Pretax Margin (TTM)":"25.18","Pretax Margin (Annual)":"25.64","Operating Margin (5Y)":"24.98","Pretax Margin (5Y)":"25.21","Free Operating Cash Flow/Revenue (5Y)":"4.50","Free Operating Cash Flow/Revenue (TTM)":"-8.49","Gross Margin (5Y)":"90.90","Net Profit Margin (5Y)":"21.76"},"Management Effectiveness":{"Return on Assets (Annual)":"13.03","Return on Equity (TTM)":"10.70","Return on Average Equity (Annual)":"16.50","Return on Average equity (TTM)":"14.74","Return on Investment (Annual)":"14.88","Return on Investment (TTM)":"11.76","Return on Average Assets (5Y)":"14.54","Return on Average Equity (5Y)":"18.26","Return on Investment (5Y)":"16.66","Asset Turnover (Annual)":"0.59","Asset Turnover (TTM)":"0.50","Inventory Turnover (Annual)":"1.02","Inventory Turnover (TTM)":"1.19","Net Income/Employee (Annual)":"167,351.80","Net Income/Employee (TTM)":"162,767.80","Receivables Turnover (Annual)":"10.00","Receivables Turnover (TTM)":"7.68","Revenue/Employee (Annual)":"759,042.30","Revenue/Employee (TTM)":"755,329.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-11.76","Revenue Growth Rate (5Y)":"14.23","EPS Growth (Quarterly YoY)":"-17.01","EPS Growth (TTM YoY)":"-2.29","EPS Growth Rate (5Y)":"18.58","Dividend Growth Rate (3Y)":"34.38","Revenue Growth (TTM YoY)":"8.13","Revenue Growth (Per Share 5Y)":"11.68","Revenue Growth Rate (3Y)":"8.65","EPS Growth Rate (3Y)":"12.86","Book Value Growth Rate (Per Share 5Y)":"20.98","Tangible Book Value Total Equity CAGR (5Y)":"18.57","Capital Spending growth rate 5 year":"60.55","EBITDA CAGR (5Y)":"17.73","EBITDA Interim CAGR (5Y)":"--","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"--","Net Profit Margin Growth Rate (5Y)":"5.96"},"Income Statement":{"Revenue (Annual)":"3,257.43","Revenue (TTM)":"3,173.14","EBITD (Annual)":"859.20","EBITD (TTM)":"718.93","Earnings Before Taxes (Annual)":"835.18","Earnings Before Taxes (TTM)":"798.98","Net Income to Common (Annual)":"718.19","Net Income to Common (TTM)":"683.79","Earnings Before Taxes Normalized (Annual)":"837.97","Net Income Available to Common Normalized (Annual)":"720.59","Diluted Normalized EPS excl. Extra Items (TTM)":"0.78"}}}